However, given that these agents could plausibly affect cardiovascular and renal outcomes positively via direct antihypertensive properties, the specific role of SGLT2 inhibitors in a person with T2DM and hypertension needs to be defined [16]. This evidence concerns the gene SLC5A2 and Hypertension.